Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Stephens & Co. Reiterates Equal-Weight on Itron, Maintains $45 Price Target

Stephens & Co. analyst Tommy Moll reiterates Itron (NASDAQ:ITRI) with a Equal-Weight and maintains $45 price target.
byBenzinga Newsdesk
February 28, 2023
1 minute read
Total
0
Shares
0
0
0
0
0
0

Stephens & Co. analyst Tommy Moll reiterates Itron (NASDAQ:ITRI) with a Equal-Weight and maintains $45 price target.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Janssen Submits Supplemental Biologics License Application To U.S. FDA Seeking Approval Of RYBREVANT Plus Chemotherapy For The Treatment Of Patients With EGFR-Mutated Non-Small Cell Lung Cancer Who Progressed On Or After Osimertinib

By Benzinga Newsdesk
November 20, 9:15 AM
This submission is supported by data from the Phase 3 MARIPOSA-2 Study featured in a Late-Breaking Presidential Symposium session at the 2023 ESMO Congress and simultaneously published in Annals of

JNJ